ArticleOncotarget2016
Rottlerin exerts its anti-tumor activity through inhibition of Skp2 in breast cancer cells.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Advances in protein ubiquitination modification and immune evasion of breast cancer.Frontiers in cell and developmental biology · 2026Review
- Unravelling the role of ubiquitin-specific proteases in breast carcinoma: insights into tumour progression and immune microenvironment modulation.World journal of surgical oncology · 2025Review
- SKping cell cycle regulation: role of ubiquitin ligase SKP2 in hematological malignancies.Frontiers in oncology · 2024Review
- Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review.Frontiers in pharmacology · 2023Review
- Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment.World journal of clinical cases · 2022Review
- Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors.Cancers · 2021Review
- Paeoniflorin inhibits cell viability and invasion of liver cancer cells via inhibition of Skp2.Oncology letters · 2020Article
- Diosgenin Exerts Antitumor Activity via Downregulation of Skp2 in Breast Cancer Cells.BioMed research international · 2020Article
- Dioscin: A new potential inhibitor of Skp2 for cancer therapy.EBioMedicine · 2020Article
- Identification of Targetable Pathways in Oral Cancer Patients via Random Forest and Chemical Informatics.Cancer informatics · 2019Article
- Rottlerin promotes autophagy and apoptosis in gastric cancer cell lines.Molecular medicine reports · 2018Article
- Targeting Protein Quality Control Mechanisms by Natural Products to Promote Healthy Ageing.Molecules (Basel, Switzerland) · 2018Review
- Paeoniflorin exerts antitumor effects by inactivating S phase kinase-associated protein 2 in glioma cells.Oncology reports · 2018Article
- Tumor suppressive role of rottlerin in cancer therapy.American journal of translational research · 2018Review
- Paeoniflorin inhibits cell growth and induces cell cycle arrest through inhibition of FoxM1 in colorectal cancer cells.Cell cycle (Georgetown, Tex.) · 2018Article
- Genistein inhibits the S-phase kinase-associated protein 2 expression in breast cancer cells.Experimental and therapeutic medicine · 2018Article
- Rottlerin inhibits cell growth and invasion via down-regulation of EZH2 in prostate cancer.Cell cycle (Georgetown, Tex.) · 2018Article
- Inhibition of Notch-1 pathway is involved in rottlerin-induced tumor suppressive function in nasopharyngeal carcinoma cells.Oncotarget · 2017Article
- S-phase kinase-associated protein 2 promotes cell growth and motility in osteosarcoma cells.Cell cycle (Georgetown, Tex.) · 2017Article
- Nitidine chloride inhibited the expression of S phase kinase-associated protein 2 in ovarian cancer cells.Cell cycle (Georgetown, Tex.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies have investigated the tumor suppressive role of rottlerin in carcinogenesis. However, the molecular mechanisms of rottlerin-induced anti-tumor activity are largely unclear. Skp2 (S-phase kinase associated protein 2) has been validated to play an oncogenic role in a variety of human malignancies. Therefore, inactivation of Skp2 could be helpful for the treatment of human cancers. In the current study, we explore whether rottlerin could inhibit Skp2 expression, leading to inhibition of cell growth, migration and invasion in breast cancer cells. We found that rottlerin treatment inhibited cell growth, induced apoptosis and cell cycle arrest. We also revealed that rottlerin suppressed cell migration and invasion in breast cancer cells. Mechanically, we observed that rottlerin significantly down-regulated the expression of Skp2 in breast cancer cells. Importantly, overexpression of Skp2 abrogated rottlerin-mediated tumor suppressive activity, whereas down-regulation of Skp2 enhanced rottlerin-triggered anti-tumor function. Strikingly, we identified that rottlerin exhibited its anti-tumor potential partly through inactivation of Skp2 in breast cancer. Our findings indicate that rottlerin could be a potential safe agent for the treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.